If you do not find your required case in this list please send us email. We can help you to get it. Cases List given below of all publishers:
Download Case Solution Biopure is the company associated with research and development of substitute blood in the medical market. Oxyglobin and Hemopure are the two products of the company under discussion. Oxyglobin is a substitute product for animals, and Hemoglobin is made for the human market.
The motive of Biopure is to enter the human market with an evolutionary substitute for blood, helping in the transfusion process worldwide.
Oxyglobin has been approved by FDA; whereas, the company has to wait for the approval of Hemopure by FDA, a primary requirement before the launch of every medical product.
Oxyglobin and Hemopure possess the same physical characteristics and look similar to each other. The launch of Oxyglobin at a low price would result in a lower price expectation for Hemopure, resulting in loss of the potential profitability of the company.
The timing and pricing of Oxyglobin should be designed in such a way that the potential of Hemopure is not jeopardized in the market. How might Oxyglobin be a threat to Hemopure? How might it be an asset to Hemopure?
What should Biopure do regarding the commercial release of Oxyglobin? If they release, what price should they set? How should it be distributed?Mar 08, · Biopure Technology Case Study Case study for Biopure Technology The case explained the current situation of the Biopure Corporation at the point of making a strategic decision.
Biopure Case Study Essay Words | 12 Pages Estimated Market Demand for Oxyglobin 13 Exhibit 3: Estimation of veterinary Market and per year 14 Exhibit 4: Financial Projections – Sensitivity Analysis 15 Executive Summary In , Biopure Corporation is one of the three legitimate contenders in the emerging field of “blood .
Access to case studies expires six months after purchase date. Publication Date: May 29, It is early and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten. Biopure Corp.’s former head of regulatory affairs has settled with the U.S.
Securities and Exchange Commission for his role in an alleged scheme to promote the company's blood substitute. • Biopure Corporation, founded in , privately owned pharmaceutical firm.
Comparative Analysis Option 1 Option 2 Builds up Market reputation before the launch of Hemopure. Brings in revenues through sales and IPO which can be used in promotion of Hemopure. Feedback on public acceptance of blood substitutes.
Distribution network . It is early and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten-year history, has just received government approval to release Oxyglobin, a revolutionary new "blood substitute" designed to replace the need for donated animal blood in the veterinary market.